ClinicalTrials.gov
ClinicalTrials.gov Menu

2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00191971
Recruitment Status : Completed
First Posted : September 19, 2005
Last Update Posted : November 6, 2007
Sponsor:
Information provided by:
Eli Lilly and Company

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : No date given
  Actual Study Completion Date : September 2006